Literature DB >> 19494512

Neutrophilic inflammation and CXC chemokines in patients with refractory asthma.

Shinya Kikuchi1, Izumi Kikuchi, Yotaro Takaku, Takehito Kobayashi, Koichi Hagiwara, Minoru Kanazawa, Makoto Nagata.   

Abstract

BACKGROUND: There is evidence that eosinophils and neutrophils are simultaneously increased in the airways of some patients with chronic refractory asthma. The mechanisms by which neutrophils accumulate in the airways of asthmatics remain to be elucidated, however, chemoattractants for neutrophils such as CXC chemokines may affect either the accumulation or functional status of neutrophils in such patients. The objective of the present study was to identify the CXC chemokine responsible for the neutrophilic and possibly eosinophilic inflammation observed in the airways of patients with refractory asthma.
METHODS: Following the inhalation of hypertonic saline, induced sputum was obtained from 14 healthy controls, 16 patients with mild well-controlled nonrefractory asthma, and 14 patients with refractory asthma. Concentrations of CXC chemokines and differential inflammatory cell counts were determined.
RESULTS: The percentages of induced sputum eosinophils were significantly higher both in patients with nonrefractory asthma and in patients with refractory asthma. On the other hand, the percentages of neutrophils were increased only in sputum from patients with refractory asthma. The concentration of IL-8, but not ENA-78 or GRO-alpha, was also significantly increased in induced sputum from patients with refractory asthma. The concentration of IL-8 correlated significantly with the percentages of neutrophils.
CONCLUSIONS: The results of the present study suggest that IL-8, but not ENA-78 or GRO-alpha, may contribute to the observation of neutrophilic inflammation in patients with refractory asthma. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19494512     DOI: 10.1159/000211379

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  8 in total

1.  Prostaglandin I(2) analogues enhance growth-related oncogene-alpha expression in human monocyte-derived dendritic cells.

Authors:  Chang-Hung Kuo; Ren-Long Jan; Yu-Te Chu; Wei-Li Wang; Ming-Yii Huang; Ching-Hua Huang; Tai-Heng Chen; Chih-Hsing Hung
Journal:  Inflammation       Date:  2010-10       Impact factor: 4.092

2.  Trans-basement membrane migration of eosinophils induced by LPS-stimulated neutrophils from human peripheral blood in vitro.

Authors:  Fuyumi Nishihara; Kazuyuki Nakagome; Takehito Kobayashi; Toru Noguchi; Ryuichiro Araki; Yoshitaka Uchida; Tomoyuki Soma; Makoto Nagata
Journal:  ERJ Open Res       Date:  2015-12-22

Review 3.  Asthma Biomarkers: Do They Bring Precision Medicine Closer to the Clinic?

Authors:  Ioana Agache; Liliana Rogozea
Journal:  Allergy Asthma Immunol Res       Date:  2017-11       Impact factor: 5.764

Review 4.  Involvement and Possible Role of Eosinophils in Asthma Exacerbation.

Authors:  Kazuyuki Nakagome; Makoto Nagata
Journal:  Front Immunol       Date:  2018-09-28       Impact factor: 7.561

Review 5.  NETopathic Inflammation in Chronic Obstructive Pulmonary Disease and Severe Asthma.

Authors:  Mohib Uddin; Henrik Watz; Anna Malmgren; Frauke Pedersen
Journal:  Front Immunol       Date:  2019-02-05       Impact factor: 7.561

Review 6.  Innate Immune Responses by Respiratory Viruses, Including Rhinovirus, During Asthma Exacerbation.

Authors:  Kazuyuki Nakagome; Makoto Nagata
Journal:  Front Immunol       Date:  2022-06-20       Impact factor: 8.786

7.  Proteolytic Activity Present in House-Dust-Mite Extracts Degrades ENA-78/CXCL5 and Reduces Neutrophil Migration.

Authors:  Laura Keglowich; Michael Tamm; Jun Zhong; Nicola Miglino; Pieter Borger
Journal:  J Allergy (Cairo)       Date:  2014-05-04

Review 8.  Mechanisms of eosinophilic inflammation.

Authors:  Makoto Nagata; Kazuyuki Nakagome; Tomoyuki Soma
Journal:  Asia Pac Allergy       Date:  2020-04-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.